|Tested species reactivity||Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||C-terminal of Prostate Specific Membrane Antigen|
|Storage buffer||tissue culture supernatant|
|Contains||15mM sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||1:50|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA5-14579 targets Prostate Specific Membrane Antigen in IHC (P) applications and shows reactivity with Human samples.
The MA5-14579 immunogen is c-terminal of Prostate Specific Membrane Antigen.
Prostate Specific Membrane Antigen (PSMA) is a surface glycoprotein with restricted expression to normal prostate tissue, primary and metastatic prostate cancer and the neovasculature of various nonprostatic epithelial malignancies. Overexpression of PSMA is correlated with high tumor grade, non-diploid tumors, and advanced tumor stage. Even though PSA is useful in identifying the prostate origin of cancers, PSMA shows moderate to strong positivity in one-half of the cells per case that show relatively poor PSA staining, and is excellent in differentiating between prostatic adenocarcinoma and urothelial carcinoma. PSMA is expressed in 94.3% to 100% of primary and 57.7%–100% of metastatic prostatic carcinomas. PSMA is recognized as a viable target for cancer therapy.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.